EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.

Autor: Semmlinger, Anna1 anna.semmlinger@med.uni-muenchen.de, von Schoenfeldt, Viktoria2 victoria.schoenfeldt@med.uni-muenchen.de, Wolf, Verena2 verena-wolf@gmx.net, Meuter, Alexandra1 alexandra.meuter@med.uni-muenchen.de, Kolben, Theresa Maria1 theresa.kolben@med.uni-muenchen.de, Kolben, Thomas1 thomas.kolben@med.uni-muenchen.de, Zeder-Goess, Christine1 christine.goess@med.uni-muenchen.de, Weis, Florian3 florian.c.weis@gmail.com, Gallwas, Julia1 julia.gallwas@med.uni-muenchen.de, Wuerstlein, Rachel1,2 rachel.wuerstlein@med.uni-muenchen.de, Hermelink, Kerstin1 kerstin.hermelink@med.uni-muenchen.de, Schmoeckel, Elisa4 elisa.schmoeckel@med.uni-muenchen.de, Harbeck, Nadia1,2 nadia.harbeck@med.uni-muenchen.de, Mayr, Doris4 doris.mayr@med.uni-muenchen.de, Mahner, Sven1,2 sven.mahner@med.uni-muenchen.de, Jeschke, Udo1,2 udo.jeschke@med.uni-muenchen.de, Ditsch, Nina1 nina.ditsch@med.uni-muenchen.de
Zdroj: BMC Cancer. 4/16/2018, Vol. 18 Issue 1, p1-9. 9p. 1 Diagram, 3 Charts, 1 Graph.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje